# DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

> **NCT04775953** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 200 (actual)

## Conditions studied

- Staphylococcal Bacteraemia

## Interventions

- **DRUG:** Cefazolin
- **DRUG:** Dalbavancin
- **DRUG:** Daptomycin
- **DRUG:** Nafcillin
- **DRUG:** Oxacillin
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT04775953
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-22
- **Primary completion:** 2023-10-06
- **Final completion:** 2023-12-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04775953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04775953, "DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04775953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*